Back to news

CG Oncology Rises as Investors Position for Near-Term Trial Data and Aftermath of Q3 Beat

Investivoq PriceTracker

CG Oncology, Inc. (CGON) is up 6.1% today. Here is some analysis on what might have caused this price movement.

Analysis: A fresh company announcement does not appear to explain today’s gain, so the move looks tied to continued momentum from last week’s quarterly update and growing investor focus on a key Phase 3 readout expected later this month. This could be because traders are repositioning ahead of multiple late-2026 catalysts after the company posted better-than-expected quarterly figures and reiterated a strong cash runway.

Details:

  • The company’s recent quarterly update kept its November 2026 timeline for topline Phase 3 PIVOT-006 data in non-muscle invasive bladder cancer, giving investors a near-term clinical catalyst.
  • Management also reiterated plans for additional 12-month data from two other cohorts in December 2026 and said completion of its biologics license application submission is anticipated in the fourth quarter of 2026.
  • In its latest quarterly materials, the company reported about $984.5 million in cash, cash equivalents, and marketable securities, which it said should fund operations through 2029.
  • The prior earnings release also came with a smaller-than-expected quarterly loss and stronger-than-expected revenue, which can continue to support sentiment even after the initial reaction day.

    • Sources:

    CG Oncology, SEC, Yahoo Finance

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $CGON Insider Trading Activity

    CGON Insider Trades

    $CGON insiders have traded $CGON stock on the open market 11 times in the past 6 months. Of those trades, 1 have been purchases and 10 have been sales.

    Here’s a breakdown of recent trading of $CGON stock by insiders over the last 6 months:

    • BRIAN GUAN-CHYUN LIU purchased 371,085 shares for an estimated $24,814,453
    • JAMES MULAY has made 0 purchases and 3 sales selling 26,129 shares for an estimated $1,934,317.
    • LEONARD E POST has made 0 purchases and 7 sales selling 14,000 shares for an estimated $955,755.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive CGON Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $CGON Hedge Fund Activity

    We have seen 125 institutional investors add shares of $CGON stock to their portfolio, and 118 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 6,575,049 shares (+15711.0%) to their portfolio in Q2 2026, for an estimated $467,157,231
    • CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 4,059,139 shares (-98.7%) from their portfolio in Q3 2026, for an estimated $287,752,363
    • BRAIDWELL LP removed 1,870,571 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $132,904,069
    • SEVEN FLEET CAPITAL MANAGEMENT LP added 1,810,478 shares (+2389.8%) to their portfolio in Q2 2026, for an estimated $128,634,461
    • RTW INVESTMENTS, LP added 1,529,782 shares (+21.9%) to their portfolio in Q2 2026, for an estimated $108,691,011
    • AVIDITY PARTNERS MANAGEMENT LP added 1,398,948 shares (+inf%) to their portfolio in Q2 2026, for an estimated $99,395,255
    • BLACKROCK, INC. added 1,192,108 shares (+23.5%) to their portfolio in Q2 2026, for an estimated $84,699,273

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $CGON Analyst Ratings

    Wall Street analysts have issued reports on $CGON in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • Guggenheim issued a "Buy" rating on 11/09/2026
    • Wedbush issued a "Outperform" rating on 11/06/2026
    • RBC Capital issued a "Outperform" rating on 08/07/2026
    • Piper Sandler issued a "Overweight" rating on 08/07/2026
    • Truist Securities issued a "Buy" rating on 08/07/2026

    To track analyst ratings and price targets for $CGON, check out Investivoq's $CGON forecast page.

    $CGON Price Targets

    Multiple analysts have issued price targets for $CGON recently. We have seen 6 analysts offer price targets for $CGON in the last 6 months, with a median target of $85.0.

    Here are some recent targets:

    • Michael Schmitz from Guggenheim set a target price of $89.0 on 11/09/2026
    • Robert Driscoll from Wedbush set a target price of $84.0 on 11/06/2026
    • Leonid Timashev from RBC Capital set a target price of $79.0 on 08/07/2026
    • Kelsey Goodwin from Piper Sandler set a target price of $85.0 on 08/07/2026
    • Gregory Renza from Truist Securities set a target price of $85.0 on 08/07/2026
    • Andres Y. Maldonado from HC Wainwright & Co. set a target price of $100.0 on 05/18/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.